Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
Changes in the mean BCVA (logMAR units) and CMT relative to the baseline in eyes with or without the previous IVR treatment. In eyes refractory to IVR, IVA significantly reduced CMT at 6 months after IVA treatment but did not significantly improved VA at any time after IVA treatment. IVR, intravitreal ranibizumab injection; CMT, central macular thickness. relative to the baseline of the BCVA and the CMT. Data are expressed as mean ± SEM.